Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
TFF Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
TFFP
Nasdaq
8731
https://tffpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for TFF Pharmaceuticals Inc
TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering
- May 1st, 2024 9:07 pm
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
- Apr 30th, 2024 12:00 am
TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting
- Apr 29th, 2024 2:00 pm
TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions
- Apr 15th, 2024 11:00 am
TFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectations
- Apr 1st, 2024 11:21 am
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
- Mar 28th, 2024 8:05 pm
TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs
- Mar 27th, 2024 8:01 pm
TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
- Mar 25th, 2024 1:01 pm
TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Mar 22nd, 2024 7:11 pm
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
- Mar 20th, 2024 4:00 pm
TFF Pharmaceuticals Announces Update on Clinical Programs
- Mar 20th, 2024 1:03 pm
TFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024
- Mar 14th, 2024 8:47 pm
TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conference
- Jan 24th, 2024 1:00 pm
TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting
- Jan 9th, 2024 1:00 pm
TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC
- Dec 19th, 2023 11:00 am
TFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TAC
- Dec 18th, 2023 9:01 pm
TFF Pharmaceuticals Announces Reverse Stock Split
- Dec 15th, 2023 12:00 pm
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors
- Dec 13th, 2023 1:00 pm
TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors
- Nov 30th, 2023 1:00 pm
TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors
- Nov 30th, 2023 1:00 pm
Scroll